Cigarette smoking is a significant public health concern especially in cancer patients. rTMS has been investigated for smoking cessation in healthy smokers. This study will test the therapeutic benefits of rTMS for smoking cessation in cancer patients with smoking. Firstly, we will evaluate total number of smoke-free days during a 7-day quit attempt. Secondly, we will evaluate cigarette consumption and cue craving for smoking during the quit attempt period.
We recently published results from a NIDA-funded study of a brief behavioral treatment that was designed to reduce the troublesome cravings that smokers encounter when they attempt to quit smoking. This intervention was based on a growing body of neuroscience studies showing that memories for prior learning can be retrieved by the presentation of cues involved in that learning. Once retrieved, the memories enter into a brief period of vulnerability, during which they can be modified, but after which they are reconsolidated (restabilized) back into long-term storage. The treatment potential of this phenomenon was initially demonstrated in a Science report in which inpatient heroin addicts were briefly exposed to cues associated with heroin use in order to prompt the heroin use memories into a vulnerable state. Once the memories were in this state, the heroin addicts received extinction training consisting of protracted exposure to heroin associated cues. It was argued that extinction would change the memories such that the cues would no longer be associated with heroin administration and reward. Remarkably, after just two sessions of retrieval-extinction training (RET), the investigators found that craving in response to heroin cues was substantially reduced for up to 6-months post-treatment. This effect was observed relative to a control group that received retrieval involving non-heroin cues, followed by extinction. These impressive initial findings led us to replicate and extend the study in cigarette smokers. In our study, one group of smokers received two sessions of RET with smoking cues whereas a control group received the same training except that retrieval consisted of brief exposure to neutral, smoking-unrelated cues. Craving and other reactions to familiar and novel smoking cues were assessed in test sessions performed 24-hrs, 2-weeks and 1-month after intervention; smoking behavior was also assessed over 1-month follow-up. Remarkably, at 1-month follow-up, craving to both familiar and novel smoking cues was significantly lower in the group receiving R-E training vs. control. Even more striking was the 25% reduction in the number of cigarettes smoked per day in the RET group vs. control. [Also of significance was suggestive evidence that, relative to control participants, more participants in the RET group achieved a 60% reduction in smoking (from pretreatment levels)]. The proposed project will replicate and extend these findings by 1) increasing the dose of intervention so as to bolster the observed treatment effects, 2) employing brain imaging methods to identify patterns of brain activity uniquely associated with the intervention and potentially predictive of treatment outcome, 3) adding a control group that will enhance understanding of the effects of RET, and 4) extending follow-up period to more completely document the long-term effects of RET. Positive findings from this study could lead to the development of a brief, effective behavioral intervention to reduce the burden levied against society by smoking. Importantly, this intervention could be easily adapted to treat other forms of addiction and co-occurring anxiety disorders, such as PTSD.
Emphysema is a type of Chronic Obstructive Pulmonary Disease (COPD) and a major cause of death. Studies suggest that emphysema is more common in HIV positive people (HIV+) compared to HIV negative (HIV-) people. The purpose of this research study is to determine whether emphysema in HIV+ patients is clinically and biologically different compared to emphysema in those without HIV.
Screening for lung cancer at earlier, more treatable stages has the potential to reduce mortality from the U.S.'s most deadly cancer. Annual lung cancer screening with low-dose computed tomography is now recommended for high risk individuals based on age and smoking history. This study will evaluate a smoking cessation intervention for lung cancer screening patients. We will evaluate quit rates after a standard intervention (brief counseling session at time of LCS) versus a medication and text messaging intervention.
Smokers, ages 18-45, are being recruited for a research study at MUSC to help better understand patterns of cigarette smoking among male and female regular smokers. Specifically, participants will track their cigarette use using an electronic lighter and will complete surveys on a mobile device for two weeks.
The purpose of this study is to examine the accuracy of wearable technology to detect and characterize smoking behavior. The study consists of one visit and will last approximately one hour. We are seeking adult (? 18 years old) male and female smokers to participate. Compensation is available for those that qualify.
The study involves use of a new quit-smoking smartphone application. Participants will use the app for two weeks, which involves completing surveys several times a day (approx. 15 min each) and logging any smoking activity. Participants will need to make a nicotine replacement medicine (over-the-counter and study provided) aided quit-attempt. Participants will have the opportunity to make suggestions that may improve the development of the app.
This is a research study that will test a new remote monitoring technology to assess smoking in the natural environment among adolescents and young adults ages 15-25. After assessment and inclusion in the study, participants will be asked to report on their smoking by answering questions on a mobile phone for 35 days. Participants will also be asked to make a brief quit attempt lasting for approximately 48 hours. There is no cost to participate and compensation is available to those who qualify.
Smoking cessation is the most important strategy available to reduce lung cancer risk. To date, there has been no research on tobacco cessation in lung screening patients, who may have unique attributes (e.g., anxiety about having a nodule coupled with tobacco dependence). We thus propose to evaluate 2 novel behavioral interventions as adjuncts to standard pharmacotherapy. We will enroll and randomize 276 patients undergoing lung screening to Intervention 1 (gain-framed personalized video and print intervention). We will evaluate whether this will improve tobacco quit rates above and beyond standard of care smoking cessation treatment over 8 weeks. Then we will perform a second randomization to Intervention 2, an individual-level, biofeedback intervention. We will then evaluate whether this intervention will reduce smoking rates at 6 months.
This research is a randomized smoking cessation trial conducted within and specifically personalized for lung cancer screening patients presenting to a lung screening clinic. Novel tobacco treatments for this population are critically needed, given the growing population of lung screening patients. In the proposed study, we will test a gain-framed messaging intervention specifically designed for lung screening patients (vs. unframed messaging), as well as evaluating NRT sampling (vs. no medication).